Raised From The Grave: A Second Life for Sotagliflozin?

Authors:
Maren Richards Brinton, PharmD
Jonathan C. Hughes, PharmD, BCPS, BCACP

Reviewers:
Jessica Brooke Binz, PharmD, BCACP
Elisa Greene, PharmD, BCACP

Citation: Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384(2):129-139. doi:10.1056/NEJMoa2030186.

Citation: Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117-128. doi:10.1056/NEJMoa2030183.

The Problem:

The prevalence of heart failure in patients with diabetes is four-times higher than in the general population.^1,2 The direct medical cost to care for patients with heart failure is approximately $24,000 annually, and most of those costs are hospitalization-related expenses.³ As new drug classes emerge in the management of diabetes and heart failure, it is important to thoroughly evaluate available literature and identify opportunities to reduce complications and costs.